VRTX Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

Vertex reported Phase 2b inaxaplin cut UACR 42.7% in AMKD with modest proteinuria and 17.3% in AMKD with type 2 diabetes; safety was generally well tolerated. Enrollment in the Phase 2/3 AMPLITUDE trial is complete, with an interim analysis expected in early 2027.Material DetailsContext by AI Analy…